<DOC>
	<DOCNO>NCT00506571</DOCNO>
	<brief_summary>Patients treat irinotecan ( 150 mg/m2 ) follow oxaliplatin ( 85 mg/m2 ) day 1 S-1 ( 80 mg/m2/day ) day 1 14 every 3 week . Patients receive plan treatment maximum 12 cycle chemotherapy . Response assessment perform every 2 cycle chemotherapy .</brief_summary>
	<brief_title>Phase II Study Irinotecan , Oxaliplatin Plus TS-1 Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm unresectable metastatic colorectal cancer , amenable surgery radiation treatment curative intent At least one unidimensional measurable lesion ECOG performance status 02 . No prior chemotherapy metastatic setting , adjuvant neoadjuvant treatment nonmetastatic ( M0 ) disease allow complete least 6 month prior initiation study treatment Adequate major organ function Give write informed consent Prior systemic chemotherapy metastatic disease Prior treatment oxaliplatin irinotecan Prior radiotherapy permit administered target lesion select study provide complete least 4 week registration Prior surgical treatment stage IV disease permit CNS metastasis Prior history peripheral neuropathy â‰¥ NCI CTC grade 1 Uncontrolled severe cardiovascular disease Serious concurrent infection nonmalignant illness Other malignancy within past 3 year except cure nonmelanomatous skin cancer carcinoma situ cervix Organ allograft require immunosuppressive therapy Psychiatric disorder uncontrolled seizure would preclude compliance Pregnant , nurse woman patient reproductive potential without contraception Patients receive concomitant treatment drug interact S1 flucytosine , phenytoin , warfarin et al . Prior unanticipated severe reaction fluoropyrimidine therapy , know dihydropyrimidine dehydrogenase ( DPD ) deficiency Known hypersensitivity platinum compound component study medication Major surgery within 3 week prior study treatment start , lack complete recovery effect major surgery Received investigational drug agent/procedure , i.e . participation another trial within 4 week begin treatment study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>colorectal neoplasm</keyword>
	<keyword>secondary</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>